Receptor Binding: How Peptides Activate Biological Targets

Peptides exert their biological effects by binding to specific receptors — proteins on cell surfaces or within cells that recognize the peptide's three-dimensional structure and trigger downstream signaling cascades. Understanding receptor binding is essential for understanding why peptides work, why dosing matters, and why cycling is necessary.

The binding event

Receptor binding follows the lock-and-key principle, refined by the induced-fit model. A peptide (the ligand) approaches a receptor's binding pocket (the active site) and forms non-covalent interactions:

• Hydrogen bonds: Between peptide backbone or side-chain groups and receptor residues
• Ionic interactions: Between charged amino acid side chains (Lys, Arg, Asp, Glu) and complementary charges in the receptor
• Hydrophobic interactions: Nonpolar side chains (Leu, Ile, Val, Phe) pack against hydrophobic regions of the binding pocket
• Van der Waals forces: Short-range attractions from closely packed atoms

The sum of these interactions determines binding affinity — measured as the dissociation constant (Kd). A lower Kd means tighter binding. Most peptide therapeutics have Kd values in the nanomolar range (10⁻⁹ M).

Receptor types relevant to peptide pharmacology

G protein-coupled receptors (GPCRs)

GPCRs are the most common target for peptide therapeutics. They span the cell membrane seven times and signal through intracellular G proteins when activated.

Examples in peptide science:

• GLP-1 receptor: Target of semaglutide, liraglutide, tirzepatide. Gs-coupled — activates adenylyl cyclase, increases cAMP, stimulates insulin secretion
• Growth hormone secretagogue receptor (GHSR): Target of Ipamorelin, GHRP-2, GHRP-6, Hexarelin. Gq-coupled — activates phospholipase C, increases intracellular calcium
• Melanocortin receptors (MC1R–MC5R): Targets of PT-141 (bremelanotide), Melanotan II, setmelanotide. Different MC receptor subtypes mediate different effects (MC4R → sexual function, MC1R → pigmentation)
• Ghrelin receptor: Target of GHRP-6. Stimulates appetite and GH release

Receptor tyrosine kinases (RTKs)

These receptors dimerize upon ligand binding and activate intracellular kinase domains.

Examples:

• VEGFR2: Upregulated by BPC-157. Drives angiogenesis at injury sites
• GH receptor: A cytokine receptor (JAK-STAT pathway) upregulated by BPC-157. Mediates growth hormone's tissue-repair effects

Intracellular targets

Some peptides bypass cell-surface receptors entirely:

• SS-31: Penetrates the cell membrane and binds cardiolipin in the inner mitochondrial membrane
• FOXO4-DRI: Enters the cell and disrupts the FOXO4-p53 protein-protein interaction in the nucleus

Agonism, antagonism, and modulation

Full agonist: Binds the receptor and produces maximal biological response. Semaglutide is a full agonist at the GLP-1 receptor.

Partial agonist: Binds the receptor but produces submaximal response, even at saturating concentrations. Can act as a functional antagonist in the presence of a full agonist.

Antagonist: Binds the receptor without activating it, blocking the natural ligand. Few therapeutic peptides are pure antagonists.

Allosteric modulator: Binds a site other than the active site, changing the receptor's response to its natural ligand. Selank may function as an allosteric modulator of GABA-A receptors — enhancing GABA sensitivity without directly activating the receptor.

Biased agonist: Activates one signaling pathway through the receptor while not activating another. This is a frontier concept in GLP-1 receptor pharmacology — engineering peptides that activate the cAMP pathway (therapeutic) while minimizing β-arrestin recruitment (which drives desensitization and some side effects).

Selectivity and side effects

A peptide's selectivity — how specifically it binds its target receptor vs. related receptors — determines its side-effect profile.

High selectivity example: Ipamorelin binds GHSR with minimal activation of other receptors. This is why it releases GH without significantly elevating cortisol or prolactin (unlike GHRP-6, which has broader receptor activity).

Low selectivity example: Melanotan II activates MC1R (pigmentation), MC3R (energy homeostasis), MC4R (sexual function, appetite), and MC5R. This broad melanocortin activity produces the full spectrum of effects — tanning, appetite suppression, sexual arousal, and nausea.

Receptor desensitization

Prolonged or repeated receptor activation triggers desensitization — the cell's mechanism for preventing overstimulation:

1. Phosphorylation: G protein-coupled receptor kinases (GRKs) phosphorylate the activated receptor
2. β-arrestin recruitment: β-arrestin binds the phosphorylated receptor, blocking G protein coupling
3. Internalization: The receptor is endocytosed (pulled inside the cell), reducing cell-surface receptor density
4. Downregulation: With chronic stimulation, receptor gene expression decreases, reducing total receptor number

This process explains why cycling is necessary for many peptides — particularly GH secretagogues. Hexarelin causes faster GHSR desensitization than Ipamorelin, which is why Hexarelin cycles are shorter (4–6 weeks) vs. Ipamorelin (12–16 weeks).

Implications for peptide dosing

Receptor pharmacology directly informs dosing strategy:

• Dose-response curves flatten: Above a certain dose, all receptors are occupied. More peptide doesn't produce more effect — it just increases side effects from off-target binding
• Pulsatile dosing: For GH secretagogues, pulsatile administration mimics natural GH release patterns and reduces desensitization compared to continuous exposure
• Fasting state matters: Insulin and free fatty acids occupy overlapping signaling pathways. Elevated insulin blunts GH secretagogue response — hence the fasting requirement
• Cycling preserves sensitivity: Off-periods allow receptor resynthesis and upregulation, restoring baseline sensitivity